Literature DB >> 20356985

Idiopathic pulmonary fibrosis and pirfenidone.

H R Collard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20356985     DOI： 10.1183/09031936.00006610

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  7 in total

1.  Pirfenidone in idiopathic pulmonary fibrosis.

Authors:  J Swigris; D Fairclough
Journal:  Eur Respir J       Date:  2010-09       Impact factor: 16.671

2.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

3.  Pirfenidone treatment of idiopathic pulmonary fibrosis.

Authors:  Ye Gan; Erica L Herzog; Richard H Gomer
Journal:  Ther Clin Risk Manag       Date:  2011-02-08       Impact factor: 2.423

Review 4.  Novel therapeutic approaches for pulmonary fibrosis.

Authors:  Arnab Datta; Chris J Scotton; Rachel C Chambers
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.

Authors:  Arata Azuma; Yoshio Taguchi; Takashi Ogura; Masahito Ebina; Hiroyuki Taniguchi; Yasuhiro Kondoh; Moritaka Suga; Hiroki Takahashi; Koichiro Nakata; Atsuhiko Sato; Shoji Kudoh; Toshihiro Nukiwa
Journal:  Respir Res       Date:  2011-10-28

Review 6.  Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.

Authors:  Hannah V Woodcock; Philip L Molyneaux; Toby M Maher
Journal:  Drug Des Devel Ther       Date:  2013-06-19       Impact factor: 4.162

7.  Fibrocytes and the pathogenesis of diffuse parenchymal lung disease.

Authors:  Borna Mehrad; Robert M Strieter
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.